Cavendish Corporate Finance
Founded in 1988, Cavendish specializes in mid-market mergers & acquisitions (M&A), advising private companies, public enterprises, and financial institutions. They offer services including equity fundraising, valuations, due diligence, debt refinancing, deal negotiation, and M&A advisory. Their expertise spans industries such as consumer retail, healthcare, business services, chemicals, financial services, telecom, media, and technology.
Top Stages
1 past transactions
Shield Therapeutics
Post in 2023
Shield Therapeutics is an independent specialty pharmaceutical company based in Wollerau, Switzerland, concentrating on the development and commercialization of late-stage, mineral-derived pharmaceuticals aimed at addressing significant unmet medical needs. The company’s primary focus is on its lead product, Feraccru, which is designed for the treatment of iron deficiency anemia associated with inflammatory bowel disease, as well as chronic kidney disease. Additionally, Shield Therapeutics is advancing PT20, a product intended for the management of hyperphosphatemia, which is nearing the final stages of development. The company generates most of its revenue from the Feraccru segment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.